Ask about this productRelated genes to: CKMM protein
- Gene:
- CKM NIH gene
- Name:
- creatine kinase, M-type
- Previous symbol:
- CKMM
- Synonyms:
- -
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-02-10
Related products to: CKMM protein
Related articles to: CKMM protein
- Epidemiological data and the comorbidity situation of cardiovascular-kidney-metabolic disease (CKM) in ethnic minority regions of southern China are lacking. This study aimed to (1) estimate the prevalence and stage distribution of CKM syndrome and (2) identify factors associated with CKM stages and explore the interrelationships among coexisting chronic conditions in a multi-ethnic population in southern China. - Source: PubMed
Publication date: 2026/04/22
Li KehuiZeng YingMo ManqiuXu YunanLi XiaohuaXu YuanshanNong ZhiqiangPan LingHuang Rongjie - Amid the cardiovascular-kidney-metabolic (CKM) syndrome public health crisis, this study aimed to explore differential pathological associations with established versus advanced CKM status and assess its consistency across Chinese and U.S. adults. - Source: PubMed
Publication date: 2026/04/22
Zhang TengMan Zi-YueZhang Shi-MengMu Jian-JunLiao Yue-Yuan - The cardiovascular-kidney-metabolic (CKM) syndrome is a major public health challenge driven by intertwined cardiometabolic and renal dysfunction. Diet-related inflammation and oxidative stress may accelerate biological aging, as reflected by DNA methylation age acceleration, thereby contributing to CKM progression and mortality. However, these pathways have not been comprehensively examined. - Source: PubMed
Publication date: 2026/05/07
Wu ShuangLyu SiqiYang ZhenkunGu TianshuWang YimengWang JuanZhu JunYang YanminChen YangZheng Lihui - Cardiovascular-kidney-metabolic (CKM) syndrome, defined by the American Heart Association in 2023, describes the interconnected risks of metabolic dysfunction, chronic kidney disease and cardiovascular disease. By unifying these conditions, CKM highlights shared pathophysiology, overlapping risk factors and common therapeutic approaches. The staging framework, from ideal CKM health (stage 0) to clinical cardiovascular disease (stage 4), underscores the importance of prevention and captures the escalating risk of morbidity and mortality with advancing stage. Epidemiological data demonstrate increasing global prevalence and that most adults already meet criteria for stage ≥1 CKM syndrome, with stage 2 (defined by metabolic risk factors or the presence of kidney disease) being the most common. The burden of CKM syndrome is characterized by demographic, socio-economic and geographic disparities, with men and older adults most affected. Established determinants of CKM health include genetics, diet, smoking and physical inactivity, as well as social and structural factors; emerging environmental risk factors, such as climate-related stressors, are increasingly investigated but have a less established evidence base. Lifestyle interventions remain foundational and modern therapeutic classes - including glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists - offer multisystem benefits, although cost, access and variable uptake remain important barriers. Here, we examine current CKM epidemiological evidence and highlight priorities for prevention, equity and future research. - Source: PubMed
Publication date: 2026/05/07
Mavromatis Lucas AGrams Morgan E - Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disease that leads to multiple organ dysfunction and high rates of cardiovascular adverse outcomes. This cross-sectional study examines the prevalence and associated risk factors of different stages of CKM syndrome in noncardiac surgery patients. - Source: PubMed
Publication date: 2026/02/26
Lang YanqiXu YanLi WenZhang Aihua